Cantor Fitzgerald Reaffirms Neutral Rating for Amedisys (NASDAQ:AMED)

Cantor Fitzgerald reiterated their neutral rating on shares of Amedisys (NASDAQ:AMED) in a report published on Thursday morning, Benzinga reports. They currently have a $101.00 price objective on the health services provider’s stock.

Several other analysts also recently weighed in on AMED. William Blair downgraded Amedisys from an outperform rating to a market perform rating in a research note on Monday, July 1st. StockNews.com upgraded Amedisys from a hold rating to a buy rating in a research note on Saturday, May 4th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of Hold and an average target price of $100.67.

Amedisys Stock Up 0.5 %

Amedisys stock opened at $98.25 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.09. The business’s 50-day simple moving average is $94.89 and its two-hundred day simple moving average is $93.82. The company has a market cap of $3.21 billion, a PE ratio of -153.51, a PEG ratio of 2.38 and a beta of 0.79. Amedisys has a fifty-two week low of $89.55 and a fifty-two week high of $98.95.

Institutional Trading of Amedisys

A number of hedge funds have recently modified their holdings of AMED. Water Island Capital LLC boosted its stake in shares of Amedisys by 185.0% in the fourth quarter. Water Island Capital LLC now owns 710,697 shares of the health services provider’s stock worth $67,559,000 after buying an additional 461,368 shares during the last quarter. Norges Bank acquired a new position in Amedisys in the 4th quarter worth about $34,032,000. Segantii Capital Management Ltd acquired a new position in Amedisys in the 4th quarter worth about $32,776,000. Calamos Advisors LLC acquired a new position in Amedisys in the 4th quarter worth about $23,015,000. Finally, Alpine Associates Management Inc. raised its holdings in Amedisys by 23.0% in the 4th quarter. Alpine Associates Management Inc. now owns 1,271,097 shares of the health services provider’s stock worth $120,830,000 after purchasing an additional 237,600 shares during the period. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.